Subtype
Astrocytic Tumor
CI-CAN-00001839Explore in graph →
Non-malignant507 active trials2 approved drugs67 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001839Explore in graph →
Clinical trials
1,861 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02926222 | Regorafenib in Relapsed Glioblastoma(REGOMA) | completed | Phase 2 | 119 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Sep 9, 2022 | clinicaltrials |
| NCT03744026 | Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9(SC9-GBM-01) | completed | Phase 1 / Phase 2 | 38 | CarTheraINDUSTRY | 2 | Sep 7, 2022 | clinicaltrials |
| NCT03856099 | TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab | terminated | Phase 2 | 19 | PharmAbcineINDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT02302235 | Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study(GBMXRT) | completed | Phase 2 | 42 | Mid-Atlantic Epilepsy and Sleep Center, LLCOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT03022578 | Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT01884740 | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | terminated | Phase 1 / Phase 2 | 13 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT00731731 | Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 125 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2022 | clinicaltrials |
| NCT01062425 | Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 2 | 261 | National Cancer Institute (NCI)NIH | 1 | Jul 26, 2022 | clinicaltrials |
| NCT01609790 | Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | completed | Phase 2 | 137 | National Cancer Institute (NCI)NIH | 2 | Jul 21, 2022 | clinicaltrials |
| NCT05447195 | Phase 2 Study of CAN008 in Subjects With GBM | unknown | Phase 2 | 117 | CANbridge Life Sciences Ltd.INDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03367715 | Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma | completed | Phase 2 | 10 | NYU Langone HealthOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT02968940 | Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma | completed | Phase 2 | 6 | NYU Langone HealthOTHER | 1 | Jun 29, 2022 | clinicaltrials |
| NCT02663271 | TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma | terminated | Phase 2 | 10 | University of FloridaOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT00479765 | A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma | terminated | Phase 1 / Phase 2 | 4 | Boston Scientific CorporationINDUSTRY | 1 | Jun 22, 2022 | clinicaltrials |
| NCT02330562 | Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab | completed | Phase 1 / Phase 2 | 121 | CelgeneINDUSTRY | 2 | Jun 8, 2022 | clinicaltrials |
| NCT01434602 | Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2022 | clinicaltrials |
| NCT00669669 | O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas | terminated | Phase 1 / Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT03216499 | HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma(PT2385) | completed | Phase 2 | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT03641326 | Sunitinib in Sarcomas of the Central Nervous System | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02794883 | Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma | completed | Phase 2 | 36 | Northwestern UniversityOTHER | 1 | Apr 18, 2022 | clinicaltrials |
| NCT01004874 | Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma | completed | Phase 2 | 80 | Duke UniversityOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT02750891 | A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas | completed | Phase 1 / Phase 2 | 18 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT04065087 | Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Genexine, Inc.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT02343224 | Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas | completed | Phase 2 | 9 | Emory UniversityOTHER | 1 | Jan 24, 2022 | clinicaltrials |
| NCT03400917 | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma | unknown | Phase 2 | 55 | Aivita Biomedical, Inc.INDUSTRY | 1 | Dec 16, 2021 | clinicaltrials |
| NCT00805961 | RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM | completed | Phase 2 | 68 | SCRI Development Innovations, LLCOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT04888611 | Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma | unknown | Phase 2 | 40 | Huashan HospitalOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT01856933 | BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) | completed | Phase 2 | 6 | Heinrich Elinzano, MDOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05131711 | Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG)(CSREIG) | unknown | Phase 1 / Phase 2 | 60 | Beijing Tiantan HospitalOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT01189266 | Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma | completed | Phase 1 / Phase 2 | 79 | National Cancer Institute (NCI)NIH | 3 | Oct 28, 2021 | clinicaltrials |
| NCT01587144 | Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM) | terminated | Phase 2 | 18 | Spectrum Pharmaceuticals, IncINDUSTRY | 2 | Oct 19, 2021 | clinicaltrials |
| NCT00112502 | Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme | completed | Phase 2 | 178 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 18, 2021 | clinicaltrials |
| NCT02770378 | A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 10 | University of UlmOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT03906448 | FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma(FORWARD) | terminated | Phase 2 | 1 | University of FloridaOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT02844439 | Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma | completed | Phase 2 | 40 | Kadmon Corporation, LLCINDUSTRY | 1 | Sep 22, 2021 | clinicaltrials |
| NCT02283944 | TMS Electrochemotherapy for Glioblastoma Multiforme | withdrawn | Phase 2 | 0 | University of AarhusOTHER | 0 | Sep 20, 2021 | clinicaltrials |
| NCT03034135 | Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma | completed | Phase 2 | 23 | Cantex PharmaceuticalsINDUSTRY | 1 | Sep 13, 2021 | clinicaltrials |
| NCT03243851 | Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma(METT) | completed | Phase 2 | 81 | Yong-Kil HongOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT05033587 | Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma. | unknown | Phase 2 | 28 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT01110876 | Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 1 / Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT01120639 | Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform(Tx-Treatment) | completed | Phase 1 / Phase 2 | 30 | Stanford UniversityOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT00879437 | Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma | completed | Phase 2 | 38 | Baylor College of MedicineOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT01051557 | Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 / Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 19, 2021 | clinicaltrials |
| NCT02798406 | Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects(CAPTIVE) | completed | Phase 2 | 49 | DNAtrix, Inc.INDUSTRY | 2 | Jul 15, 2021 | clinicaltrials |
| NCT01520870 | Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT. | completed | Phase 2 | 49 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Jul 6, 2021 | clinicaltrials |
| NCT02046187 | Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma | terminated | Phase 1 / Phase 2 | 14 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Jun 16, 2021 | clinicaltrials |
| NCT02743078 | Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma | terminated | Phase 2 | 3 | RTOG Foundation, Inc.OTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT03008148 | Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM | unknown | Phase 2 / Phase 3 | 288 | Johnpro Biotech, Inc.INDUSTRY | 1 | May 11, 2021 | clinicaltrials |
| NCT04874506 | MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) | unknown | Phase 2 | 55 | Matrix Biomed, Inc.INDUSTRY | 1 | May 5, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Sep 9, 2022source: clinicaltrials